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Abstract
Systemic lupus erythematosus (SLE) pre-
dominantly affects young women in their 20s.
In 40 out of 250 (16%) patients with SLE seen
in our hospital disease onset occurred after
the age of 50. The interval between the time of
onset and diagnosis was five years in this
older group compared with three years in the
younger group. Arthritis, as a first symptom,
was less common in the older onset group.
During the foilow up a lower incidence of
arthritis, malar rash, photosensitivity, and
nephropathy was found in the older onset
group. In contrast, this group showed an
increased incidence of myositis. High titres of
anti-dsDNA tended to occur less often and
the incidence of anti-Ro antibodies was lower
in the older onset group. These features seem
to distinguish patients with older onset SLE
as a particular subset.
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Systemic lupus erythematosus (SLE) pre-
dominantly affects young women in their 20s.
In 10-200/o of patients, however, the diagnosis is
made for the first time in the fifth decade of life
or later.' 2
Several investigators have reported that age at
onset has a modifying effect on disease expres-
sion. In comparison with younger patients,
elderly patients with SLE are reported to have a
more insidious onset of disease and less com-
mon occurrence of the classic manifestations of
SLE."9 Thus the correct diagnosis is often not
made for several years and is established only
after extensive diagnostic evaluation.2 3 It has
also been noted that certain features of SLE
usually associated with severity, such as
nephritis or central nervous system dysfunction,
are less common in patients with older-onset
SLE.' 2 In addition, serological abnormalities
have also been reported to be different in elderly
patients.2 The disparity in selection criteria
for patient inclusion, the age limits adopted, or
the defmition of age at onset make comparison
of findings in previous reports very difficult.
In this study, to determine whether any
relation exists between disease patterns and age
at onset, we analysed prospectively the clinical
course and immunological features in a series of
250 unselected patients with SLE.
Patients and methods
PATIENTS
Two hundred and fifty patients with SLE
consecutively attending the Hospital Clinic of
Barcelona as inpatients or outpatients between
Alfons Lopez-Soto, Margarita Navarro,
1980 and 1988 were studied prospectively. All
were white and met the American Rheumatism
Association revised criteria for SLE. 10 In 40 the
onset of disease, defined as the initial manifes-
tation clearly attributable to SLE, occurred
after the age of 50, and they represent the older
onset group described in this report. The
remaining 210 patients were diagnosed before
the age of 50, and they represent the younger
onset group. The age limit was established
arbitrarily according to previous reports. 1-9
Follow up ranged between four months and
seven years (mean 63 (SD 54) months) with no
significant differences between groups.
A detailed clinical and laboratory assessment
according to a pre-established protocol was
made of each patient, including (a) age at
diagnosis; (b) evidence of clinical renal disease
(abnormal urine sediment, proteinuria greater
than 500 mg/day, or otherwise unexplained
increase of serum creatinine above 110 pmol/l);(c) occurrence of chronic renal failure; (d)
central nervous system disease; (e) cutaneous
involvement; (t) serositis (including pleuritis,
pericarditis, or both); and (g) Raynaud's
phenomenon.
Disease was judged to be clinically active
when the following signs or symptoms were
present (a) typical dermatitis; (b) arthritis; (c)
serositis; (d) central nervous system abnor-
malities (recent onset of chorea, seizures,
psychosis, organic brain syndrome in the absence
of offending drugs or known metabolic de-
rangements, embolic cerebral vascular acci-
dents); (e) thrombocytopenia (<OOx0IO/l); (f)
haemolytic anaemia; (g) vasculitis (biopsy); or
(h) nephritis: recent onset of haematuria (>10
red blood cells/high power field) or casts, or
proteinuria >500 mg/24 h, or a 25% increase in
serum creatinine. The histological appearance
of renal biopsy specimens was considered to be
active when fresh cellular crescents, diffuse or
focal active proliferation of endocapillary cells,
tuft necrosis, capillary thrombosis, or vasculitis
was present.
LABORATORY STUDIES
Antinuclear antibodies were determined by
indirect immunofluorescence using mouse liver
as substrate. Antibodies to dsDNA were deter-
mined by Farr's ammonium sulphate precipi-
tation technique. Complement components (C3
and C4) were estimated by radial immuno-
diffusion and CH50 by Lachmann's haemolytic
technique. Circulating immune complexes were
detected by the microcomplement consumption
test.
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In addition, 190 patients were tested for the
presence of precipitating antibodies to soluble
nuclear add cytoplasmic antigens, including
Ro(SSA), La(SSB), nRNP, and Sm by double
immunodiffusion (Ouchterlony).
These 190 patients were also tested for the
presence of antiphospholipid antibodies, in-
cluding anticardiolipin antibodies and the lupus
anticoagulant activity. The anticardiolipin anti-
bodies were measured by an enzyme linked
immunosorbent assay (ELISA) as described by
Loizou et al" and Gharavi et al'2 with the minor
modifications of Cowchock et al'3 and our
own.'4 The flatbottomed wells of microtitre
plates (Nunc, Denmark) were coated with 30
Ri/well of cardiolipin (Sigma) suspended in
ethanol at a final concentration of 50 /ml. The
test was modified by inclusion of a measure-
ment of binding to the microtitre plates after
blocking (with l0%/o fetal calfserum in phosphate
buffered saline for two hours) without added
cardiolipin. Every individual serum sample was
tested on the same plate for binding to wells
both coated and uncoated with cardiolipin.
Results were expressed as a binding index (BI).
The average value for the samples from the
wells without cardiolipin was the non-specific
BI, and with cardiolipin was referred to as the
total BI. Thus the final specific BI was obtained
by subtraction of the non-specific BI from the
total BI. A study of 50 normal control serum
samples showed a log-normal distribution of
both IgG and IgM anticardiolipin antibody
titres. Normal values were considered when the
logarithms of the specific BI were below the
98th centile of cumulative normal distribution.
The IgG anticardiolipin antibody titre was
regarded as positive if a specific BI greater than
Table I Clinicalfeatures at the onset ofsystemic lupus erythematosus in the elderly compared
with younger patients. Results are given as number (percentage)
Manifestaions Older onset Younger onset p Value
(n=40) (n=210)
Arthritis 16 (40) 137 (65) <0 005
Malar rash 8 (20) 65 (31) NS
Photosensitivity 6 (15) 38 (18) NS
Raynaud's phenomenon 9 (23) 37 (18) NS
Vasculitis 2 (5) 10 (5) NS
Serositis 7 (18) 23 (11) NS
Nephritis 1 (3) 15 (7) NS
Pneumopathy 2 (5) 4 (2) NS
Neuropsychiatric 2 (5) 16 (8) NS
Thrombocytopenia 4 (10) 13 (6) NS
Haemolytic anaemia 3 (8) 5 (2) NS
Fever 5 (13) 42 (20) NS
Myositis 4 (10) 7 (3) NS
Table 2 Incidence of major clinical features during follow up of elderly compared unth
younger patients. Results are given as nwnber (percentage)
Manifestations Older onset Younger onset p Value
(n=40) (n=210)
Arthritis 26 (65) 172 (82) <0-02
Malar rash 11 (28) 118 (56) <0-002
Photosensitivity 6 (15) 71 (34) <0-002
Raynaud's phenomenon 12 (30) 60 (29) NS
Vasculitis 5 (13) 28 (13) NS
Serositis 13 (33) 63 (30) NS
Nephritis 8 (20) 83 (40) <0 03
Pneumopathy 4 (10) 8 (4) NS
Neuropsychiatric 5 (13) 44 (21) NS
Thrombocytopenia 10 (25) 44 (21) NS
Haemolytic anaemia 5 (13) 14 (7) NS
Fever 16 (40) 92 (44) NS
Myositis 8 (20) 15 (7) <0-02
Cardiomyopathy 1 (3) 13 (6) NS
Thrombosis 6 (15) 31 (15) NS
2 85 (SD 3 77) was detected. A specific BI
greater than 4 07 (3 90) was defined as positive
for IgM anticardiolipin antibodies. The lupus
anticoagulant activity was detected by the
method of Exner.'5
STATISTICAL ANALYSIS
Conventional x2 and Fisher's exact tests were
used for analysing qualitative differences,
Student's t test for comparison of means in large
samples of similar variance, and the non-
parametric Mann-Whitney U test for small
samples for age differences between groups.
Results
PATIENTS
In 40 patients (16%) disease onset occurred after
the age of 50. The mean age of this group at
disease onset was 58 years (range 50-78) com-
pared with 32 years (8-48) for the younger onset
patients. The interval between the time of onset
and diagnosis was five years in the older group
compared with three years in the younger group
(p<0 05). The male/female ratio was 4/1 in the
older group in contrast with 9/1 in the younger
one. All women in the older group were in the
menopause at disease onset.
CLINICAL MANIFESTATIONS
Table 1 shows the presenting clinical manifesta-
tions for patients with disease onset before or
after age 50. The older group less often showed
arthritis as a first symptom (p<0005). During
the follow up analysis of cumulative clinical
symptoms showed that the most significant
difference between these two groups was a
decreased incidence of arthritis (p<0 02), malar
rash (p<0 002), photosensitivity (p<0002),
and nephropathy (p<0 03) in the older onset
group. In contrast, this group had a significantly
increased incidence of myositis (p<0 02) (table
2).
The incidence of other clinical features,
including serositis, pulmonary disease, and
central nervous system manifestations, did not
differ significantly between the groups.
IMMUNOLOGICAL ABNORMALITIES
Table 3 gives the serological findings in relation
to age. High titres of anti-dsDNA tended to
occur less frequently in the older onset group
(p<0-05), with a similar proportion of clinically
active patients in both groups, indicating that
titres of anti-dsDNA decreased with aging. The
Table 3 Serological features at the onset of systemic lupus
erythematosus tn the elderly compared vith younger patients.
Results are given as mean (SD)
Varable Older onset YoMger onset p Value
(n=40) (n=210)
dsDNA (U/ml) 33-9 (31-7) 50 4 (39-2) <0 05
C3 (mg/i) 728 (216) 678 (259) NS
C4 (mg/i) 239 (166) 220 (139) NS
CH50 (units) 411 (234) 391 (202) NS
CICs (%) 22-8 (20 2) 29-0 (21-0) NS
CIC=circulating immune complexes.
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Table 4 Incidence of antiphospholipid antibodies and antibodies to extractable nuclear
antigens at the onset ofdisease ofelderly compared withyounger patients. Results are given as
number (percentage)
Antbodies Older onset Younger onset p Value
(n=40) (n= 150)
Antiphospholipid antibodies 25 (63) 58 (39) <0C01
Ro(SSA) 4 (10) 57 (38) <0-02
La(SSB) 2 (5) 22 (15) NS
nRNP 2 (5) 25 (17) NS
Sm 5 (13) 27(18) NS
incidence of detection of serum complement
fractions (C3, C4, CH50) was similar in both
groups.
The incidence of antiphospholipid antibodies
(anticardiolipin antibodies or lupus anti-
coagulant, or both) was higher in elderly patients
(p<0-01). In contrast, the incidence of anti-Ro
antibodies was lower in this group of patients
(p<002). No significant differences were found
in the incidence of the other antibodies to
extractable nuclear antigens between the two
groups (table 4).
Discussion
Systemic lupus erythematosus is a chronic
inflammatory disorder of unknown cause with a
wide spectrum of both clinical and immuno-
logical features. Although it has traditionally
been considered a disease of young women,
several reports have described SLE in the
elderly. `9 Nevertheless, overall experience
with older-onset SLE is not extensive and the
precise prevalence of clinical and serological
findings differs from study to study.' 2 4 6 1-19
In our series 40 out of 250 patients with SLE
(16%) developed the disease after the age of
50-a prevalence similar to that noted by
others' 2 4 using similar criteria for selection
of patients. In addition, although some
authors2 6 7 found no difference in the female/
male ratio with aging, our observations suggest
that female predominance is not so pronounced
in the elderly onset group.
The clinical expression of SLE in elderly
patients differs in several aspects from the
disease in young adults.1-9 The presenting
manifestations in the patients with older onset
disease are interesting, and best resemble those
in patients with drug induced SLE, primary
Sjogren's syndrome, or polymyalgia rheu-
matica. 1 4 7 8 Thus in our series musculoskeletal
manifestations, including myositis mimicking
polymyalgia rheumatica, were common.
Although some authors' 6 7 16 have reported
that serositis and pulmonary disease were the
most common presenting features in their
patients, we found a similar incidence of these
manifestations in both groups. In addition, our
patients share many similarities with other
patients with older onset SLE previously
reported, including a low incidence of lupus
nephropathy and classical arthritis and cutan-
eous involvement. 1 2 7
Age also influences the serological manifesta-
tions of SLE. Lower anti-dsDNA titres were
found in our patients with older onset SLE.
Similar results have been reported by Wilson et
al.4 It has been suggested that antibodies to Ro
and La are more prevalent in elderly patients
and might be a useful aid in establishing the
diagnosis of SLE.2 6 7 In our study, however,
the prevalence of these antibodies tended to
decrease in the older onset group. Similar
results have been found by others./0 Interest-
ingly, we found a higher prevalence of anti-Sm
antibodies, both in younger and elderly patients,
than previously reported in other European
studies.2' We also detected a higher prevalence
of antiphospholipid antibodies in the elderly
group. This is in agreement with the findings of
Manoussakis et al22 that anticardiolipin anti-
bodies are commonly found in the elderly
population.
Interestingly, the initial diagnosis in the older
group was tardy, presumably because doctors
are reluctant to diagnose SLE in elderly patients
and because atypical signs and symptoms in this
age group are common. This is reflected in our
series in the mean five year delay in establishing
the diagnosis of SLE in the older onset group.
High clinical awareness is important as it is
expected that increasing numbers of people will
survive into the later years of life during the
next decades. Thus it is reasonable to expect
that more patients with older onset SLE will be
diagnosed in the future.6 23
Although the explanation for this apparently
age related variability in expression of the
disease is still unclear, demographic factors and
differences in genetic predisposition or respon-
siveness of an aging immune system may be
implicated.3 8 It has been suggested that older
and younger patients may have different genetic
determinants of disease and respond to different
triggering mechanisms.623 Alternatively, the
less exuberant expression of SLE both clinically
and immunologically in older patients may
reflect senescence of the immune system.24
Our knowledge of the clinical and epidemio-
logical aspects of SLE in the elderly has
increased substantially in the last few years.
Many questions await further analysis from a
genetic and immunological perspective,
however.
Supported in part by grants from the Hospital Clinic i Provincial
of Barcelona to Dr Ricard Cervera and Dr Alfons Lopez-Soto.
1 Baker S B, Rovira J R, Campion G V, Mills J A. Late onset
systemic lupus erythematosus. AmJ Med 1979; 66: 727-32.
2 Hochberg M C, Boyd R E, Ahearn J H. Systemic lupus
erythematosus: a review of clinicolaboratory features and
immunogenetic markers in 150 patients with emphasis on
demographic subsets. Mediine(Baltimore) 1985;64:285-95.
3 Foad B S I, Sheon R P, Kirsner A B. Systemic lupus
erythematosus in the elderly. Arch Intern Med 1972; 130:
743-6.
4 Wilson H A, Hamilton M E, Spyker D A, et al. Age
influences the clinical and serological expression of systemic
lupus erythematosus. Arthritis Rhewn 1981; 24: 1230-5.
S Bailou S P, Khan M A, Kushner I. Clinical features of
systemic lupus erythematosus. Differences related to race
and age of onset. Arthritis Rheum 1982; 25: 55-60.
6 Catoggio L J, Skinner R P, Smith G, Maddison P J.
Systemic lupus erythematosus in the elderly: clinical and
serological characteristics. J Rheumatol 1984; 11: 175-81.
7 Maddison P J. Systemic lupus erythematosus in the elderly.
J Rheumatol 1987; 14 (suppl 13): 182-7.
8 Hashimoto H, Tsuda H, Hirano T, Takasaki Y, Matsumoto
T, Hirose S. Difference in clinical and immunological
findings of systemic lupus erythematosus related to age.
J Rheunatol 1987; 14: 497-501.
9 Jonsson H, Nived 0, Sturfelt G. The effect of age on clinical
and serological manifestations in unselected patients with
systemic lupus erythematosus. J Rhumatol 1988; 15:
505-9.
704
 group.bmj.com on July 6, 2011 - Published by ard.bmj.comDownloaded from 
Systemic lupus erythematosus in the elderly
10 Tan E M, Cohen A S, Fries J F, et al. The 1982 revised
criteria for the classification ofsystemic lupuserythematosus.
Arthritis Rhewm 1982; 25: 1271-7.
11 Loizou S, McCrea J D, Rudge A C, Reynolds R, Boyle C C,
Harris E N. Measurement of anticardiolipin antibodies by
an enzyme-linked immunosorbent assay (ELISA);
standardization and quantitation of results. Clin Exp
Imnmnol 1985; 62: 738-45.
12 Gharavi A E, Harris E N, Asherson R A, Hughes G R V.
Anticardiolipin antibodies: isotype distribution and phos-
pholipid specificity. Ann Rhewn Dis 1987; 46: 1-6.
13 Cowchock S, Fort J, Munoz S, Norberg R, Maddrey W.
False positive ELISA tests for anticardiolipin antibodies in
sera from patients with repeated abortion, rheumatologic
disorders and primary biliary cirrhosis: correlation with
elevated polyclonal IgM and implications for patients with
repeated abortion. Clin Exp Immuwol 1988; 73: 289-94.
14 Cervera R, Font J, L6pez-Soto A, et al. Isotype distribution
of anticardiolipin antibodies in systemic lupus erythe-
matosus: prospective analysis of a series of 100 patients.
Arm Rheum Dis 1990; 49: 109-13.
15 Exner T, Rickard K A, Kronenberg H. Studies on phospho-
lipids in the action of a lupus coagulation inhibitor.
Pathology 1975; 7: 319-28.
16 Dinant J, Ginzler E M, Schlesinger M, et al. Systemic lupus
erythematosus in the older age group: computer analysis.
Am Geriatr Soc 1979; 27: 58-1.
17 Urowitz M B, Stevens M B, Shulman L E. The influence of
age in the clinical pattern of systemic lupus erythematosus.
Artkritis Rheum 1%7; 10: 319-20.
18 Gossat D M, Walls B. Systemic lupus erythematosus in later
life. MedI Aust 1982; 1: 297-9.
19 Baer A N, Pincus T. Occult systemic lupus erythematosus in
elderly men. JAMA 1983; 249: 3350-2.
20 Bell D A, Rigby R, Stiller C R, Clark W F, Harth M, Ebers
G. HLA antigens in systemic lupus erythematosus: re-
lationship to disease severity, age at onset, and sex.
J Rhewnatl 1984; 11: 475-9.
21 Clotet B, Guardia J, Pigrau C, et al. Incidence and clinical
significance of anti-ENA antibodies in systemic lupus
erythematosus. Estimation by counterimmunoelectro-
phoresis. ScandJ Rhewnatol 1984; 13: 15-20.
22 Manoussakis M N, Tzioufas A G, Silis M P, Pange P J E,
Goudevenos J, Moutsopoulos H M. High prevalence of
anti-ardiolipin and other autoantibodies in a healthy
elderly population. Clin Exp Immunol 1987; 69: 557-65.
23 Bell D A. SLE in the elderly. Is it really SLE or systemic
Sjogren's syndrome?J Rhewnatol 1988; 15: 723-4.
24 Stevens M B. Connective tissue disease in the elderly. Clin
Rhen Dis 1986; 12: 11-32.
705
 group.bmj.com on July 6, 2011 - Published by ard.bmj.comDownloaded from 
doi: 10.1136/ard.50.10.702
 1991 50: 702-705Ann Rheum Dis
 
J Font, L Pallarés, R Cervera, et al.
 
characteristics.
elderly: clinical and immunological 
Systemic lupus erythematosus in the
 http://ard.bmj.com/content/50/10/702
Updated information and services can be found at: 
These include:
References
 http://ard.bmj.com/content/50/10/702#related-urls
Article cited in: 
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on July 6, 2011 - Published by ard.bmj.comDownloaded from 
